Compositions and methods for treating vascular permeability

• US 8,841,259 B2
• Filed: 02/16/2006
• Issued: 09/23/2014
• Est. Priority Date: 02/24/2005
• Status: Active Grant

• Current Assignee: Joslin Diabetes Center Inc.
• Original Assignee: Joslin Diabetes Center Inc.
• Inventors: Feener, Edward P., Aiello, Lloyd P.
• Primary Examiner(s): NOAKES, SUZANNE MARIE
• Application Number:
  US11/884,503
• Publication Number:
  US 20080280811A1
• Time in Patent Office: 3,141 Days
• Field of Search: None
• US Class Current: 514/20.8
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12Q 1/527 involving lyase
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G01N 2800/32 Cardiovascular disorders
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere

Abstract

The present invention provides methods and composition for the treatment and diagnosis of disorders associated with excessive vascular permeability and edema.

Claims

1. A method of decreasing retinal vascular permeability in the eye of a human subject, the subject having increased retinal vascular permeability or edema in the eye, the method comprising administering to the subject a therapeutically effective amount of DX-88 (SEQ ID NO:

1).

2. The method of claim 1, wherein the administering is local administration to the eye of the subject.

3. The method of claim 2, wherein the local administration is by injection into the vitreous or aqueous humor of the eye.

4. The method of claim 1, wherein said subject has diabetic macular edema, proliferative diabetic retinopathy, or nonproliferative diabetic retinopathy.

5. The method of claim 1, wherein said subject has macular degeneration.

6. The method of claim 1, wherein said subject has a retinal vein occlusion.

7. A method of decreasing retinal vascular permeability in the eye of a subject, the subject having increased retinal vascular permeability or edema in the eye, the method comprising administering to the subject a therapeutically effective amount of complement-1 inhibitor polypeptide.

8. The method of claim 7, wherein the administering is local administration to the eye of the subject.

9. The method of claim 8, wherein the local administration is by injection into the vitreous or aqueous humor of the eye.

10. The method of claim 7, wherein said subject has diabetic macular edema, proliferative diabetic retinopathy, or nonproliferative diabetic retinopathy.

11. The method of claim 7, wherein said subject has macular degeneration.

12. The method of claim 7, wherein said subject has a retinal vein occlusion.

13. The method of claim 7, wherein said subject s a human.

14. A method of decreasing retinal vascular permeability in the eye of a human subject, the subject having increased retinal vascular permeability or edema in the eye, the method comprising administering to the subject a therapeutically effective amount of an anti-prekallikrein antibody or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment recognizes human prekallikrein.

17. The method of claim 14, wherein said subject has diabetic macular edema, proliferative diabetic retinopathy, or nonproliferative diabetic retinopathy.

18. The method of claim 14, wherein said subject has macular degeneration.

19. The method of claim 14, wherein said subject has a retinal vein occlusion.

15. The method of dam 14, wherein the administering is local administration to the eye of the subject.

16. The method of claim 15, wherein the local administration is by injection into the vitreous or aqueous humor of the eye.